Australia - English - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - sodium valproate, quantity: 1000 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; phosphoric acid; sodium hydroxide; water for injections - sodium valproate wockhardt is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

Australia - English - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - sodium valproate, quantity: 400 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; phosphoric acid; sodium hydroxide; water for injections - sodium valproate wockhardt is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - sodium valproate, quantity: 400 mg - injection, solution - excipient ingredients: water for injections - sodium valproate juno is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 500 mg - tablet, enteric coated - excipient ingredients: hyprolose; calcium silicate; amaranth aluminium lake; titanium dioxide; polyvinyl acetate phthalate; diethyl phthalate; stearic acid; purified talc; povidone; hypromellose; magnesium stearate; macrogol 6000; indigo carmine aluminium lake; citric acid monohydrate - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 200 mg - tablet, enteric coated - excipient ingredients: citric acid monohydrate; polyvinyl acetate phthalate; indigo carmine aluminium lake; hyprolose; magnesium stearate; povidone; stearic acid; amaranth aluminium lake; diethyl phthalate; purified talc; macrogol 6000; calcium silicate; hypromellose; titanium dioxide - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - sodium valproate, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic potassium phosphate; water for injections; nitrogen - valproate-aft is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - sodium valproate, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: monobasic potassium phosphate; dibasic sodium phosphate dodecahydrate; water for injections; nitrogen - valproate-aft is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - sodium valproate, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: dibasic sodium phosphate dodecahydrate; nitrogen; water for injections; monobasic potassium phosphate - valproate-aft is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - sodium valproate, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections; monobasic potassium phosphate; dibasic sodium phosphate dodecahydrate; nitrogen - valproate-aft is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - sodium valproate, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: nitrogen; dibasic sodium phosphate dodecahydrate; monobasic potassium phosphate; water for injections - valproate-aft is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.